Plus Therapeutics Inc. (NASDAQ:PSTV) does about 432.83K shares in volume on a normal day but saw 9715498 shares change hands in Tuesday trading. The company now has a market cap of 12.06M USD and an enterprise value of about $7.75M. Its current market price is $2.83, marking an increase of 15.51% compared to the previous close of $2.45. The 52 week high reached by this stock is $16.00 whilst the lowest price level in 52 weeks is $0.93. The script in recent trading has seen the stock touch a high of $2.99 and a low of $2.40.
Plus Therapeutics Inc. (PSTV) has a 20-day trading average at $2.72 and the current price is -82.31% off the 52-week high compared with 203.97% distance from its 52-week low. The 50-day simple moving average of the closing price is $2.49 and its 200-day simple moving average is $2.10. If we look at the stock’s price movements over the week, volatility stands at 11.25%, which decreases to 10.81% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 57.19 to suggest the stock is neutral.
1 analysts observing the Plus Therapeutics Inc. (PSTV) stock have set the 12-month price targets for the company’s shares at between $5.00 and $5.00. The median price target is 43.4% away from the current levels at $5.00.
FactSet Research has provided data showing that 1 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Moderate Buy the stock.
The current price level is 4.35%, 13.98%, and 34.71% away from its SMA20, SMA50, and SMA200 respectively, with the PSTV price moving below the 50-day SMA on September 01. Plus Therapeutics Inc. (PSTV) stock is up 15.51% over the week and 8.85% over the past month. Its price is 17.92% year-to-date and -78.82% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of -$0.45 above consensus estimates by $0.3. The company’s next earnings report is expected on 11/05/2020, with forecasts estimating quarterly EPS at -$0.65 and -$2.04 for whole year. PSTV’s earnings per share are forecast to grow by 75.30% this year and -32.40% over next year.
Its 12-month price target is $5.00. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $5.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $5.00.
Outstanding shares total 4.05M with insiders holding 0.74% of the shares and institutional holders owning 18.84% of the company’s common stock. The company has a return on investment of -29.50% and return on equity of -176.00%. The beta has a value of 0.53. Price to book ratio is 3.49 and price to sales ratio is 1.91.
According to a U.S. Securities and Exchange Commission filing, Vanguard Extended Market Index Fu has reduced its position in Plus Therapeutics Inc. (PSTV) to 15,281 shares, mirroring a recent drop by 0.00%. Vanguard Extended Market Index Fu dumped 0.0 shares of Plus Therapeutics Inc. common stock bringing its total worth to about $37133.0 at the end of recent close, SEC documents show. Vanguard Extended Market Index Fu isn’t the only investment manager who changed stakes and is followed by Fidelity Extended Market Index Fu, which sold off 0.0 shares to end up with 6,336 shares worth $15396.0. USAA Extended Market Index Fund raise their holdings by 0.46% in the company over the course of the most recent quarter. It now holds a 0.02% position in Plus Therapeutics Inc. thanks to 650.0 shares amounting to $1580.0.